A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

NCT02927301 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

181

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

Sponsor

Genentech, Inc.